Efpeglenatide
Efpeglenatide is a GLP-1 receptor agonist under development for the treatment of type 2 diabetes and obesity and reducing the risk of cardiovascular incidents in people with these conditions.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Efpeglenatide is a GLP-1 receptor agonist under development for the treatment of type 2 diabetes and obesity and reducing the risk of cardiovascular incidents in people with these conditions. Its developer is Hanmi Pharmaceutical.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1360608000 under CC BY-SA 4.0; modifications have been made.